Investors Buy Large Volume of Monte Rosa Therapeutics Call Options (NASDAQ:GLUE)

Posted by Stanley Muller on Oct 19th, 2026

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 2,011 call options on the stock. This represents an increase of approximately 369% compared to the average volume of 429 call options.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Monte Rosa Therapeutics during the second quarter valued at about $165,603,000. Jupiter Topco LLC bought a new position in Monte Rosa Therapeutics in the 2nd quarter valued at about $25,965,000. Opaleye Management Inc. bought a new position in Monte Rosa Therapeutics in the 2nd quarter valued at about $18,029,000. Janus Henderson Group PLC bought a new position in Monte Rosa Therapeutics in the 1st quarter valued at about $11,294,000. Finally, Nantahala Capital Management LLC acquired a new position in Monte Rosa Therapeutics during the 2nd quarter valued at about $15,778,231. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE traded up $0.21 during midday trading on Monday, hitting $9.95. 243,483 shares of the stock traded hands, compared to its average volume of 1,359,728. The business’s 50 day moving average price is $12.97 and its two-hundred day moving average price is $17.33. The firm has a market capitalization of $848.61 million, a PE ratio of -5.64 and a beta of 1.37. Monte Rosa Therapeutics has a 1-year low of $8.94 and a 1-year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $8.97 million during the quarter, compared to analyst estimates of $12.91 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. As a group, equities research analysts forecast that Monte Rosa Therapeutics will post -1.23 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on GLUE. Benchmark restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, October 5th. Raymond James Financial set a $25.00 target price on Monte Rosa Therapeutics in a report on Monday, October 5th. HC Wainwright started coverage on Monte Rosa Therapeutics in a research report on Thursday, October 1st. They set a “buy” rating and a $25.00 price target on the stock. TD Cowen raised Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, UBS Group reissued a “buy” rating and issued a $19.00 price target (up from $17.00) on shares of Monte Rosa Therapeutics in a report on Sunday, October 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Monte Rosa Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Check Out Our Latest Research Report on GLUE

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions.